Comparison · NCT00105469-c67f72fe
AzaSite vs Tobramycin: Number of Participants Who Achieved Bacterial Eradication at Visit 3
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. AzaSite vs Tobramycin: Number of Participants Who Achieved Bacterial Eradication at Visit 3. Trial comparisons, record NCT00105469-c67f72fe. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00105469-c67f72fe
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.881 | 0.821 | 0.922 | wilson | |
| Risk in group 2 | 0.943 | 0.895 | 0.97 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0622 | -0.128 | 0.00139 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.934 | 0.872 | 1 | log | |
| Odds ratio, group 1 over group 2 | 0.448 | 0.196 | 1.02 | log | |
| Number needed to treat, for one fewer participant with the outcome on AzaSite than on Tobramycin | 16.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | AzaSite | 140 | 159 | OG000 | |
| Group 2 | Tobramycin | 148 | 157 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Who Achieved Bacterial Eradication at Visit 3
- Description
- Bacterial eradication is defined as eradication of the causative pathogens as indicated by the absence of growth (0 colony forming units/mL) of the original infecting organism(s).
- Time frame
- Visit 3 (Day 6)
- Population
Per protocol population (defined as all randomized~subjects who had administered at least one drop of the appropriate study drug, demonstrated evidence of~pathogenic bacteria levels, presented clinical signs of conjunctivitis at Visit 1, and returned for at least one post-first dose clinical assessment) with last observation carried forward.
Source ClinicalTrials.gov
Trial
- Title
- Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
- NCT number
- NCT00105469
- Phases
- PHASE3
- Conditions
- Bacterial Conjunctivitis
- Interventions
- AzaSite, Tobramycin
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2011-10-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00105469?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00105469-c67f72fe